Introduction
Prostate cancer is the second most frequently diagnosed cancer and the sixth most deadly cancer in males worldwide [
1‐
3]. In the USA, prostate cancer is the most commonly diagnosed cancer in males over the age of 50 years and ranks as the second deadliest cancer in males [
4,
5]. Traditional treatments for prostate cancer include prostectomy, radiation therapy, chemotherapy and hormone deprivation therapy [
5]. These treatments can impair the quality of life for patients and thus new approaches to combating prostate cancer are warranted [
4]. Several groups are exploring methods for harnessing the immune system to recognize and kill prostate cancer cells [
2]. One such effort has led to Sipuleucel-T, a licensed, autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer [
6]. Additional immunotherapies for prostate cancer now under development include a number of vaccine candidates, as well as approaches using targeted monoclonal antibodies (mAbs) [
7].
Prostate-specific membrane antigen (PSMA) is expressed many fold higher on prostate cells than cells of other tissues, and it is considered an important clinical biomarker of prostate cancer [
8‐
10]. Levels of PSMA are further elevated on prostate cancer cells, and studies indicate a strong correlation between increased PSMA expression and prostate cancer progression [
4,
5]. PSMA expression levels can also be elevated on other malignant cells including those of urologic origin (i.e., kidney and bladder) suggesting this glycoprotein may play a role in their oncogenic progression as well [
11]. In other solid tumors including colon, ovarian, breast, and kidney cancers, elevated PSMA expression has been observed on tumor neovasculature, but not normal vasculature suggesting a role for PSMA in angiogenesis [
12]. Unlike prostate-specific antigen (PSA), PMSA is a membrane protein which makes it an attractive target to develop mAbs against it for diagnostic and therapeutic purposes [
13]. Several therapeutic anti-PSMA mAbs have been developed, and many of these have been used in radioimmunotherapy for targeting cytotoxic radionucleotides, specifically to PSMA-expressing cells [
5]. Some anti-PSMA mAbs, such as clone 2C9, have been demonstrated to mediate a therapeutic effect by promoting an antibody-dependent cellular cytotoxicity (ADCC) effect that kills prostate cancer cells [
5,
14].
DNA plasmids have been used for over 25 years as a non-viral method of in vivo gene delivery, and they have been studied extensively as a platform for vaccines and gene therapy. Recently, our group has explored developing synthetic DNA plasmids as a means of delivering the genes of MAbs that neutralize infectious agents. We have reported that constructs expressing DNA-encoded monoclonal antibody (DMAb) can direct in vivo production of functional levels of antibody targeting human immunodeficiency, dengue, and chikungunya viruses in mice [
15‐
17]. Such an approach possesses several advantages over both conventional protein-based mAbs and viral vector-based delivery of antibody genes including; (1) lower production costs; (2) the ability to generate durable, high levels of in vivo antibody production without gene integration; and (3) the ability for repeated administrations due to the non-immunogenic nature of DNA plasmids. While early applications of DNA plasmid technology suffered due to poor in vivo transgene production, recent enhancements in the design of DNA vectors along with new delivery methods including adaptive in vivo electroporation (EP) have combined to boost transgene expression to potent levels in clinical vaccine studies, without compromising safety [
18].
This study describes the first application of enhanced synthetic DNA plasmid technology to deliver DNA directing the in vivo production of a human MAb for cancer immunotherapy. We designed a novel construct encoding a therapeutic anti-PSMA MAb, and we show that this plasmid expresses DMAb in vitro and in vivo in mice after EP-enhanced intramuscular delivery. The in vivo generated antibodies retain their ability to bind specifically to PSMA, and they possess ADCC activity. Finally, we show that this anti-PSMA-DMAb can control the growth of a PSMA-positive tumor in a mouse model, likely through engagement of NK cells.
Materials and methods
Cell lines and reagents
Cell lines used in this study were purchased from American Type Culture Collection (ATCC). The 293T(ATCC
®CRL-3216™) and transgenic adenocarcinoma mouse prostate (TRAMP)-C2 (ATCC
®CRL-2731™) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco-Life Technologies) supplemented with 10% FBS and 1% penicillin/streptomycin. Lymph node carcinoma of the prostate (LNCaP) clone FGC (ATCC
®CRL-1740™) cells were maintained in RPMI-1640 (Gibco-Life Technologies) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin [
19]. The commercial anti-PSMA control mAb was obtained from R&D systems.
PSMA-DMAb plasmid construction and expression confirmation
To construct the PSMA-DMAb , the genes of both the variable heavy (
V
H) and variable light (
V
L) fragments of a human anti-PSMA mAb were examined, optimized, and constructed through the use of synthetic oligonucleotides with several modifications to improve expression as previously described [
15]. DNA was formulated in water for subsequent administration into mice. An empty pVax1 expression vector was used as a negative control. Cells (293T) were transfected with the PSMA-DMAb plasmid and confirmation of PSMA-DMAb binding to recombinant human PSMA was carried out by Western blot analysis. Briefly, recombinant PSMA protein (R&D systems) was run on an SDS-PAGE gel and transferred to Immobilon-PVDF membrane (EMD Millipore). Membranes were blocked for 1 h in blocking buffer (Li-Cor Biosciences) and then incubated for 1 h with either commercial anti-PSMA mAb (R&D systems), pooled day 14 sera from PSMA-DMAb plasmid-injected mice, or supernatants from PSMA-DMAb plasmid-transfected 293T cells. Membranes were washed and then incubated for 1 h with a goat anti-human IgG 680RD antibody (Li-Cor Biosciences) and washed. Protein bands were visualized by scanning membranes with a Li-Cor Odyssey CLx scanner [
19].
Mice, plasmid administration, and IgG quantification
Animal experiments were conducted in accordance with the University of Pennsylvania Animal Care and Use Committee guidelines. B6.Cg-
Foxn1
nu
/J (C57BL/6 nude) and C57BL/6 (both from Jackson Laboratory) mice were administered 100 µg of PSMA-DMAb or pVax1 plasmid in a single 50 µl intramuscular injection into the quadriceps, followed by in vivo electroporation [
15]. For quantifying human immunoglobulin G1 (IgG1) levels, ELISA plates were coated with 1 µg/well of goat anti-human IgG-Fc fragment antibody (Bethyl) overnight at 4 °C. The following day, plates were washed with phosphate-buffered saline with 0.1% Tween-20 (PBS-T), blocked with 10% FBS in PBS-T for 2 h at room temperature, washed, incubated for 1 h at room temperature with the respective samples that were diluted with 1% FBS in PBS-T, washed, and incubated for 1 h at room temperature with HRP-conjugated goat anti-human kappa light chain antibody (Bethyl). SIGMAFAST OPD (Sigma-Aldrich) solution was added to wells and plates kept in dark for at least 10 min for color to develop. The enzymatic reaction was stopped with 1 N H
2SO
4 and plates were read at 450 nm. A standard curve was generated using purified human IgG/Kappa (Bethyl) [
15]. Binding ELISA to evaluate antibody affinity followed a similar procedure except plates were coated overnight with recombinant human PSMA and a HRP-conjugated goat anti-human IgG (H + L) (Bethyl) was used as a secondary antibody.
Flow cytometry analysis
To detect cell surface PSMA, tubes of 1.0 × 106 LNCaP or TRAMP-C2 cells were washed with phosphate-buffered saline (PBS), stained with live/dead fixable violet dead cell stain (Life Technologies) for 15 min, and then washed twice with FACS buffer (PBS + 1% FBS). Cells were next incubated for 30 min at room temperature with a 1:4 dilution of day 14 sera from PSMA-DMAb plasmid-injected mice and then washed. Finally, cells were incubated in the dark for 30 min with a 1:100 dilution of PE-conjugated anti-human Fc IgG (Biolegend), followed by a final wash with FACS buffer. Samples were resuspended in 1× stabilizing fixative (BD) and analyzed the following day on an LSR18 flow cytometer (BD Biosciences). FACS analysis was performed on a gated low forward scatter and side scatter with Annexin-V FITC and PI (Thermo Fisher) following kit protocol for the effects of PSMA-DMAb sera on LNCaP cell death.
Indirect immunofluorescence and immunohistochemistry assay
Formalin-fixed paraffin-embedded (FFPE) human tumor tissue sections (UMass Cancer Center Tissue and Tumor Bank, Massachusetts, MA) were deparaffinized with xylene and rehydrated. Antigen retrieval was performed using a 1× working solution of citrate buffer, pH 6.0 (Sigma-Aldrich), at 100 °C for 15 min. Tissue sections were blocked with 1× PBS containing 5% normal goat serum (Cell Signaling Technology) and 0.3% Triton X-100 in a humid chamber. Tissues were washed in 1× PBS and incubated with pooled day 14 PSMA-DMAb plasmid-administered mice sera diluted 1:100 in antibody diluent. Tissues were washed in 1× PBS and incubated with a 1:500 dilution of Alexa Fluor 488-conjugated goat anti-human IgG (H + L) secondary antibody (Thermo Fisher Scientific) in antibody diluent for 1 h. Cell nuclei were counterstained with Hoechst reagent (Sigma-Aldrich). Images were acquired using the Leica TCS SP8 confocal laser scanning microscope at the cell and developmental biology microscopy core, University of Pennsylvania, PA, USA. Paraffin-embedded mouse prostate tissue was subjected to antigen retrieval and deparaffinized. Slides were then fixed with acetone and washed with PBS and sections blocked using normal goat serum followed by staining with human PSMA antibody, followed by a biotinylated goat anti-mouse and completion of immunohistochemical procedure according to the manufacturer’s instructions (Vector Labs).
Antibody-dependent cell-mediated cytotoxicity assay
ADCC activity of PSMA-DMAb was examined using Promega’s ADCC Reporter Bioassay Kit. Briefly, target LNCaP cells were incubated for 6 h at 37 °C with the engineered Jurkat effector cells and pooled day 14 sera from PSMA-DMAb plasmid-injected mice. Luciferase activity was measured by luminescence to determine ADCC activity as recommended by the manufacturer. All sera samples were tested in triplicate.
Tumor challenge
For tumor implantation, C57BL/6 male mice were injected subcutaneously with 1 × 106 TRAMP-C2 cells in the right hind flank. The experimental mice were divided into treatment groups (n=10). Animals were monitored for tumor growth. As tumors became detectable, electronic calipers were used to measure the length and width of the tumor and the tumor volumes were calculated by applying the following equation: \({\text {volume\;{(V)}}} \; = {\frac{4}{3}\times{3.14159}\times\left(\frac {{\text{length}}}{2}\times\frac {{\text{width}}}{2}\times\frac {{\text{width}}}{2}\right)}\). Under the University of Pennsylvania Animal Care and Use Committee guidelines mice are sacrificed when tumor diameter reaches 2 cm, or when tumors became ulcerated. Survival differences between groups were analyzed by Students t test, p > 0.05 is considered significant.
In vivo NK cell depletion
Mice were treated for NK cell depletion on day −1 (before tumor challenge) and at days +2 and +4 after tumor inoculation with intravenous injection of 100 μl (25 μg) of either control IgG or anti-Asialo GM1 IgG (Wako Chemicals, Richmond, VA, USA) diluted in PBS. Cells were stained with anti-NK1.1 and anti-CD3 monoclonal antibodies and analyzed by flow cytometry to verify the depletion of the CD3−/NK1.1+ (NK) cell population in the anti-Asialo GM1-treated animals.
Statistical analysis
GraphPad Prism 6 (GraphPad Software, Inc.) program was used for statistical analysis of the data. The data from ELISA assays are expressed as mean ± SD and are representative of at least three different experiments. Comparisons between individual data points were made using Student’s t test. p values < 0.05 were considered to be statistically significant.
Discussion
The work presented here describes the construction and characterization of a novel DNA plasmid-based delivery system that can be used to generate protective levels of a therapeutic mAb in vivo. A DNA plasmid encoding the
V
H and
V
L segments of a human anti-PSMA mAb was constructed and demonstrated to direct the expression of full-length, antigen-specific IgG in vitro and in vivo following electroporation-enhanced injection into the muscles of mice. PSMA is highly expressed on prostate carcinoma as well as other tumor cells, and it is considered an attractive target for antibody-based therapy due to its expression on the surface of cells. PSMA-DMAb in the serum of mice injected with PSMA-DMAb plasmid was able to bind to PSMA on the surface of the TRAMP-C2 and LNCaP prostate tumor cell lines and to sections of bladder and kidney tumors. Serum antibody levels of 1–2 μg/ml were achieved in mice injected with the PSMA-DMAb plasmid by day 14 post-administration, and the antibody remained detectable in the sera for several weeks. Importantly, PSMA-DMAb retained the ability to recognize PSMA on the surface of implanted tumor cells and to mediate a potent anti-tumor response in vivo, due at least in part through interacting with NK cells to mediate ADCC/ADCP of tumor cells. ADCC has been hypothesized to be the major mechanism mediating the anti-tumor activity of mAbs targeting diverse malignancies [
7].
Several mAbs targeting tumor-specific antigens or immunomodulatory molecules are in use or under development for cancer immunotherapy regimens, but there are impediments to their widespread use [
7,
31]. One of the primary impediments involves the cost of the treatment regimen stemming from the laborious, time-consuming manufacturing and purification processes associated with making these protein-based drugs [
2,
7,
14]. Additionally, multiple infusions of mAbs are often required to attain and maintain their efficacy, which imposes further cost and logistical constraints on patients [
31]. Given these challenges, alternative approaches to generate and deliver mAbs are important. Gene-based administration approaches are focused on delivering the genes encoding protective antibodies so that the antibodies can be generated in vivo in a sustained manner. Several groups have developed viral vectors for delivery of mAb genes and have shown that these vectors can be used to drive production of mAbs in vivo [
2,
13]. However, viral vector delivery of genes carries its own challenges, such as high development and distribution costs as well as the potential for neutralization of gene delivery and the inability to re-dose patients because of immune responses generated against the viral vector.
In this regard, the DNA plasmid-based delivery system described here possesses many unique advantageous features for use as a specific patient treatment. Primary among these is the potential for significantly lower costs stemming from lower manufacturing costs of DNA plasmids, as well as lower distribution costs because DNA is more stable and simple to produce. Synthetic DNA vectors delivered into muscle or skin with the aid of adaptive electroporation can produce high and durable levels of in vivo transgene expression without integration, and there is abundant clinical data that speaks to its favorable safety profile [
18]. Since DNA plasmids are non-immunogenic, multiple administrations of the same or different plasmids can be contemplated for delivery. This feature is particularly important if serum antibody levels decrease or another antibody treatment is required.
This is the first report describing the use of a DNA plasmid-based delivery system to direct in vivo generation of a therapeutic mAb that targets a relevant oncology target, PSMA. It is also the first report to illustrate functional engagement of host NK-immune clearance by a DNA-vectored mAb. Due to the flexibility of this platform, combination of DMAb plasmids with other anti-cancer treatments or immunotherapy agents is important to consider. Furtherr study of this approach for neoplastic disease is warranted.
Compliance with ethical standards